Plain-English translation of NCT05203913 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether giving a combination of chemotherapy drugs ( and nab-paclitaxel), an immunotherapy drug called , and radiation therapy together—right after surgery to remove bladder cancer—can help prevent the cancer from coming back. The study involves 32 patients with a specific type of bladder cancer that has invaded the muscle layer but hasn't spread to other parts of the body.
Currently, patients with this type of bladder cancer often face high rates of recurrence even after surgery. Researchers believe that combining this medication with chemotherapy and targeted radiation may work better together to kill any remaining cancer cells and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
You would start with a 6-week screening period to confirm you qualify. Then you'd receive 5 weeks of combined chemotherapy and radiation therapy, with the chemotherapy drugs given weekly through an IV and the immunotherapy drug given as an infusion every 4 weeks. After the radiation and chemotherapy end, you'll continue receiving the immunotherapy drug alone for up to 13 cycles (about a year). Throughout this time, you'll have regular check-ups every 4 weeks, and imaging scans (CT or MRI) every 4 months for the first 2 years, then every 6 months for up to 5 years to watch for any signs of cancer returning.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Italy